Date |
Symbol |
Description |
Type |
Disease |
Designation |
Success Rating |
Q3 2016
|
TNXP |
|
Phase 3 Results |
Neurology |
Special Protocol Assessment |
|
Q2 2016
|
TNXP |
|
Phase 2 Results |
Neurology |
None |
|
Q4 2016
|
MDVN |
|
Phase 3 Results |
Oncology |
None |
|
03/29/2016
|
ACAD |
|
Advisory Panel |
Neurology |
Breakthrough Therapy, Priority Review |
|
05/01/2016
|
ACAD |
|
PDUFA |
Neurology |
Breakthrough Therapy, Priority Review |
|
H2 2016
|
OXGN |
|
Phase 2 Results |
Oncology |
Orphan Drug |
|
H2 2016
|
NDRM |
|
Phase 2 Results |
Neurology |
None |
|
Q4 2016
|
PBYI |
|
Phase 2 Results |
Oncology |
None |
|
Q3 2017
|
PBYI |
|
PDUFA |
Oncology |
None |
|
Q4 2016
|
RDHL |
|
Phase 2a Results |
Neurology |
None |
|